At 7:35 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of ...

Revenue and Loss - Total revenue for the three months ended September 30, 2025, was $0, unchanged from the same period in 2024[147] - Net loss for the three months ended September 30, 2025, was $2.3 million, a decrease of $1.4 million, or 38%, from a net loss of $3.8 million in 2024[147] - Net loss for the nine months ended September 30, 2025, was $9.1 million, an increase of $1.6 million, or 21%, from a net loss of $7.5 million in 2024[151] - The company incurred a net loss of $9.1 million with no revenues generated during the nine months ended September 30, 2025, and had working capital of approximately $1.3 million[158] Expenses - Research and development (R&D) expenses decreased by $0.5 million, or 33%, to $0.9 million for the three months ended September 30, 2025, compared to $1.4 million in 2024[147] - General and administrative expenses increased by $0.6 million, or 169%, to $0.9 million for the three months ended September 30, 2025, primarily due to investor relations advertising costs[148] - Legal and professional expenses decreased by $0.9 million, or 67%, to $0.4 million for the three months ended September 30, 2025, due to lower accounting expenses compared to 2024[149] - Total operating expenses decreased by $0.8 million, or 26%, to $2.3 million for the three months ended September 30, 2025[147] - R&D expenses for the nine months ended September 30, 2025, increased by $0.9 million, or 35%, to $3.5 million compared to $2.6 million in 2024[151] - General and administrative expenses for the nine months ended September 30, 2025, increased by $2.9 million, or 297%, to $3.8 million compared to $0.96 million in 2024[151] - Total operating expenses for the nine months ended September 30, 2025, increased by $3.2 million, or 54%, to $9.1 million compared to $5.9 million in 2024[151] - R&D compensation related expenses were $1.0 million for the nine months ended September 30, 2025, a 11% increase from $0.9 million in the same period of 2024, with a decrease in percentage of total R&D expenses from 36% to 29%[152] - General and Administrative expenses increased by $2.9 million, or 297%, from $1.0 million in the nine months ended September 30, 2024, to $3.8 million in the same period of 2025[153] - Legal and professional expenses decreased by $0.6 million, or 24%, during the nine months ended September 30, 2025, compared to the same period in 2024[154] - Cash used in operating activities was $8.5 million for the nine months ended September 30, 2025, an increase of 83% from $4.6 million in the same period of 2024[172] Assets and Capital - Total current assets increased by 48% to $3.3 million as of September 30, 2025, compared to $2.2 million as of December 31, 2024[170] - As of September 30, 2025, the company had cash and cash equivalents of $2.1 million, a 1237% increase from $156,656 as of September 30, 2024[172] - The company raised approximately $5.0 million in net proceeds from a public offering in March 2025 and $3.9 million from a private placement in June 2025[166][168] Financial Instruments and Valuation - The fair value of the October 2024 Convertible Bridge Notes is calculated based on mandatory conversion scenarios and the fair value per share at the balance sheet date[183] - The company uses Monte Carlo simulation models to estimate the fair value of financial instruments, which require subjective assumptions and can lead to significant variations in measurements[190] - Changes in the fair value of derivative financial instruments are recognized in the unaudited condensed consolidated statements of operations[191] - The company evaluates all warrants issued to determine their classification and fair value, with liability-classified warrants revalued at each reporting date[188] - The fair value of warrants is estimated at issuance and recorded to additional paid-in capital for equity-classified warrants[188] - The company does not provide quantitative and qualitative disclosures about market risk as it qualifies as a smaller reporting company[194] Other Considerations - The company is evaluating options regarding the potential termination of the Theradex Master Agreement, which could materially affect its clinical trials and financial position[157] - The company has no off-balance sheet arrangements that materially affect its financial condition or results of operations[178] - Research and development expenses are charged as incurred, including product development and personnel costs, with significant involvement from former executives[180]

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has entered into a securities purchase agreement for approximately $2.5 million, which will be used for marketing, general corporate purposes, and working capital [1][2]. Group 1: Offering Details - The company will issue a pre-funded warrant to purchase up to 625,156 shares of common stock at an effective purchase price of $4.00 per share, priced above the market under Nasdaq rules [2]. - The offering is expected to close on or about November 4, 2025, subject to customary closing conditions [2][3]. Group 2: Placement Agent and Registration - WestPark Capital, Inc. is acting as the exclusive placement agent for the offering [3]. - The securities have not been registered under the Securities Act of 1933 and are offered only to accredited investors. The company has agreed to file registration statements with the SEC for the resale of shares [4]. Group 3: Company Overview - Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on improving cancer therapy outcomes by developing novel drugs that sensitize cancer cells to radiation therapy [6]. - The company's mission is to advance precision medicine approaches to radiotherapy, enhancing treatment efficacy and patient quality of life [6].

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH) Wednesday, 22 October 2025 10:00 AM Topic:Â Company Update ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Every generation has its frontier. For the last century, medicine's remained molecular: genes, proteins, receptors, the invisible mechanics of life. Today, that frontier is shifting again. The next wave isn't about what we can see under a microscope. It's about what we can teach a machine to see for us. That's the worl ...

Core Insights - Artificial intelligence has significantly impacted various industries, with drug discovery being one of the most challenging areas for its application [1] Industry Summary - Drug discovery remains a complex field where molecules exhibit unpredictable behaviors, making it difficult for algorithms to accurately predict outcomes [1]

ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment. It works, but it's a brute. ...

Rockville, Maryland--(Newsfile Corp. - October 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has entered into a binding term sheet with 1542770 BC Ltd. ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, Shuttle or one of its affiliates will acquire substantially all of Molecule's assets and liabilities for a total purchase pri ...

Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has executed a non-binding letter of intent to acquire Molecule.ai, an AI-driven company focused on transforming drug discovery and development [1][2] - Molecule.ai utilizes advanced machine learning models, including large language models, to enhance the accuracy and efficiency of evaluating novel molecules, thereby shortening development timelines and reducing costs [3][4] - The acquisition aims to integrate Molecule.ai's innovative platform into Shuttle's operations, enhancing its capabilities in drug-target interaction and autonomous drug discovery workflows [5][9] Acquisition Details - Shuttle will acquire all rights and interests of Molecule.ai, assuming all liabilities, with Molecule.ai having no further obligations post-closing [5][7] - The purchase price for the acquisition is set at $10 million, payable in cash and common shares of Shuttle, contingent upon the completion of certain milestones [7] Molecule.ai's Innovations - Molecule.ai's platform includes features such as rapid evaluation of chemical and biological properties, drug-target interaction modeling, and an autonomous framework for drug discovery workflows [9] - The introduction of the Agentic AI mode will enable AI agents to perform multi-step drug discovery processes, significantly reducing manual effort [6][9] Company Missions - Shuttle Pharmaceuticals focuses on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [10] - Molecule.ai's mission is to empower researchers with next-generation tools that lower costs and improve efficiency in therapeutic development [8]

Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has executed a non-binding letter of intent to acquire Molecule.ai, an AI company focused on transforming drug discovery and development [1][2]. Company Overview - Shuttle Pharmaceuticals is a specialty pharmaceutical company dedicated to improving cancer treatment outcomes, particularly through radiation therapy [10]. - Molecule.ai, founded by Dr. ZT Zhang, utilizes advanced machine learning and large language models to enhance the drug discovery process [8]. Acquisition Details - The acquisition involves Shuttle acquiring all rights and interests of Molecule.ai, assuming its liabilities, and Molecule.ai will have no further obligations post-closing [5]. - The purchase price for Molecule.ai is set at $10 million, payable in cash and common shares of Shuttle, contingent upon the completion of certain milestones [7]. Technological Advancements - Molecule.ai's platform offers capabilities such as rapid evaluation of chemical properties, drug-target interaction modeling, and an autonomous framework for drug discovery workflows [9]. - The introduction of the Agentic AI mode will automate multi-step drug discovery processes, significantly reducing manual efforts [6][9]. Strategic Vision - The collaboration aims to empower scientists with advanced AI tools to enhance drug discovery and expedite the development of new therapies [4].